Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1556-5170; OpenAlex author ID A5100676061. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 4 papers · 2025: 4 papers

Papers 10

  1. H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.217389↗
  2. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. Co-author DOI 10.1016/j.cmet.2025.07.008↗
  3. Prevalence and clinical relavance of germline mutations in Chinese patients with pancreatic cancer. Co-author DOI 10.1186/s12964-025-02281-1↗
  4. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/ijbs.107837↗
  5. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  6. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Co-author DOI 10.1007/s13402-023-00907-5↗
  7. Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-024-03369-3↗
  8. Ultrasound-targeted microbubble destruction improves the suppression and magnetic resonance imaging of pancreatic cancer with polyethyleneimine nanogels. Co-author DOI 10.7150/jca.93802↗
  9. Role of microenvironmental periostin in pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.11533↗
  10. Role of pancreatic stellate cells and periostin in pancreatic cancer progression. Co-author DOI 10.1007/s13277-015-3386-2↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiayu Lin · 5 shared papers, 2024–2025 · strength 1.02
  2. Pengyi Liu · 5 shared papers, 2024–2025 · strength 0.96
  3. Baiyong Shen · 5 shared papers, 2024–2025 · strength 0.95
  4. Yizhi Cao · 4 shared papers, 2024–2025 · strength 0.77
  5. Shuyu Zhai · 4 shared papers, 2024–2025 · strength 0.77
  6. Lingxi Jiang · 3 shared papers, 2024–2025 · strength 0.57
  7. Baiyong Shen · 2 shared papers, 2025 · strength 0.47
  8. Yihao Liu · 2 shared papers, 2025 · strength 0.41
  9. Yishu Huang · 2 shared papers, 2024–2025 · strength 0.41
  10. Jiejie Qin · 2 shared papers, 2024–2025 · strength 0.41
  11. Fan Li · 2 shared papers, 2017–2024 · strength 0.38
  12. Chenghong Peng · 2 shared papers, 2024–2025 · strength 0.37
  13. Chenlei Wen · 2 shared papers, 2024–2025 · strength 0.37
  14. Xiaomei Tang · 2 shared papers, 2024 · strength 0.34
  15. Yihao Liu · 2 shared papers, 2024 · strength 0.34
  16. Weishen Wang · 2 shared papers, 2024 · strength 0.34
  17. Youwei Zhu · 2 shared papers, 2024 · strength 0.34
  18. Yu Jiang · 1 shared paper, 2025 · strength 0.26
  19. Jiabin Jin · 1 shared paper, 2025 · strength 0.26
  20. Dongjie Chen · 1 shared paper, 2025 · strength 0.22
  21. Pengyi Liu · 1 shared paper, 2025 · strength 0.21
  22. Jingwei Li · 1 shared paper, 2025 · strength 0.21
  23. Jun Zhang Zhang · 1 shared paper, 2024 · strength 0.20
  24. Yu Jiang · 1 shared paper, 2025 · strength 0.20
  25. Siyi Zou · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.